# A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

> **NCT02714218** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 387 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Nivolumab 3 mg/kg IV
- **BIOLOGICAL:** Ipilimumab 1 mg/kg IV
- **BIOLOGICAL:** Nivolumab 1 mg/kg IV
- **BIOLOGICAL:** Ipilimumab 3 mg/kg IV
- **BIOLOGICAL:** Nivolumab 6 mg/kg IV

## Key facts

- **NCT ID:** NCT02714218
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-04
- **Primary completion:** 2017-04-20
- **Final completion:** 2021-05-28
- **Target enrollment:** 387 (ACTUAL)
- **Last updated:** 2022-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02714218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02714218, "A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02714218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*